Anti-Inflammatory Effects of 0.045% Tazarotene/0.01% Halobetasol Lotion in Psoriasis
Status:
Completed
Trial end date:
2023-11-13
Target enrollment:
Participant gender:
Summary
The objective of this research is to demonstrate superior anti-inflammatory effects, as
demonstrated by a reduction in TNF-a and IL-17A, with tazarotene/halobetasol lotion in
patients with mild to moderate plaque type psoriasis as compared to clobetasol propionate
0.05% cream.